Eflornithine for the treatment of human African trypanosomiasis

Parasitology Research

Volumn 90, Issue SUPPL.1, 2003, Pages

  Burri, Christian ^a   Brun, Reto ^a  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPROTOZOAL AGENT; EFLORNITHINE;

AFRICAN TRYPANOSOMIASIS; ALOPECIA; ANEMIA; BONE MARROW TOXICITY; CONVULSION; DIARRHEA; DOSE RESPONSE; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CLEARANCE; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG SYNTHESIS; EXPERIMENTAL MOUSE; EXPERIMENTAL RAT; GASTROINTESTINAL SYMPTOM; HEARING IMPAIRMENT; HUMAN; LEUKOPENIA; NAUSEA; NONHUMAN; PRIORITY JOURNAL; RABBIT; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; TRYPANOSOMA; VOMITING;

ORYCTOLAGUS CUNICULUS; TRYPANOSOMA; TRYPANOSOMA BRUCEI; TRYPANOSOMA BRUCEI GAMBIENSE; TRYPANOSOMA BRUCEI RHODESIENSE;

EID: 0038639784     PISSN: 09320113     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00436-002-0766-5     Document Type: Review

References (32)

1. Abeloff MD, Slavik M, Gordon LD, Griffin CA, Hermann J, Blanc O, Sjoerdsma A, Baylin SB (1984) Phase I trial and pharmacokinetic studies of a-difluoromethylornithine - an inhibitor of polyamine biosynthesis. J Clin Oncol 2:124-130
2. Anonymous (1991) Ornidyl patient information. Marion Merrell Dow, Kansas City, US Patent no. 4,413,141
3. Bacchi CJ, Nathan HC, Hutner SH, McCann PP, Sjoerdsma A (1980) Polyamine metabolism: a potential therapeutic target in trypanosomes. Science 210:332-334
4. Bales JDJ, Harrison SM, Mbwabi DL, Schechter PJ (1989) Treatment of arsenical refractory Rhodesian sleeping sickness in Kenya. Ann Trop Med Parasitol 83 [Suppl 1]:111-114
5. Bitonti AJ, McCann PP, Sjoerdsma A (1986) Necessity of antibody response in the treatment of African trypanosomiasis with alpha-difluoromethylornithine. Biochem Pharmacol 35:331-334
6. Blum J, Nkunku S, Burri C (2001) Clinical description of encephalopathic syndromes and risk factors for their occurrence and outcome during melarsoprol treatment of human African trypanosomiasis. Trop Med Int Health 6:390-400
7. Creaven PJ, Pendyala L, Petrelli NJ (1993) Evaluation of alpha-difluoromethylornithine as a potential chemopreventive agent: tolerance to daily oral administration in humans. Cancer Epidemiol Biomarkers Prev 2:243-247
8. Croghan MK, Aickin MG, Meyskens FL (1991) Dose-related alpha-difluoromethylornithine ototoxicity. Am J Clin Oncol 14:331-335
9. De Gee ALW, McCann PP, Mansfield JM (1983) Role of antibody in the elimination of trypanosomes after DL-a-difluoromethylornithine chemotherapy. J Parasitol 69:818-822
10. Fozard JR (1987) The contragestational effects of ornithine decarboxylase inhibition. In: McCann PP, Pegg, AE, Sjoerdsma A (eds) Inhibition of polyamine metabolism. Academic Press, London, pp 187-202
11. Giffin BF, McCann PP, Bitonti AJ, Bacchi CJ (1986) Polyamine depletion following exposure to DL-alpha- difluoromethylornithine both in vivo and in vitro initiates morphological alterations and mitochondrial activation in a monomorphic strain of Trypanosoma brucei brucei. J Protozool 33:238-243
12. Gilman TM, Paulson YJ, Cohen JL, Heseltine PNR, Boylen CT (1987) Multiple-dose pharmacokinetics of Eflornithine in AIDS patients treated for Pneumocystis carinii. Abstract book, Third International Conference on AIDS, p 188
13. Goodman-Gilman A, Rall TWR, et al. (1990) Pharmacological basis of therapeutics. Pergamon Press, New York
14. Griffin CA, Slavik M, Chien SC, Hermann J, Thompson G, Blanc O, Luk GD, Baylin SB, Abeloff MD (1987) Phase I trial and pharmacokinetic study of intravenous and oral alpha- difluoromethylornithine. Invest New Drugs 5:177-186
15. Haegele KD, Alken RG, Grove J, Schechter PJ, Koch-Weser J (1981) Kinetics of alpha-difluoromethylornithine: an irreversible inhibitor of ornithine decarboxylase. Clin Pharmacol Ther 30:210-217
16. Hardenberg J, Claverie N, Tell GP (1991) Eflornithine (Ornidyl) treatment of Trypanosoma brucei gambiense sleeping sickness; report on 711 patients treated up to March 1991. International Scientific Council for Trypanosomiasis Research and Control (ISCTRC), 21st meeting, Yamoussoukro, Kenya, p 158
17. Iten M, Matovu E, Brun R, Kaminsky R (1995) Innate lack of susceptibility of Ugandan Trypanosoma brucei rhodesiense to DL-alpha-difluoromethylornithine (DFMO). Trop Med Parasitol 46:190-194
18. Iten M, Mett H, Evans A, Enyaru JC, Brun R, Kaminsky R (1997) Alterations in ornithine decarboxylase characteristics account for tolerance of Trypanosoma brucei rhodesiense to D,L-alpha-difluoromethylornithine. Antimicrob Agents Chemother 41:1922-1925
19. Jennings FW (1988) The potentiation of arsenicals with difluoromethylornithine (DFMO): experimental studies in murine trypanosomiasis. Bull Soc Pathol Exot 81:595-607
20. McCann PP, Bacchi CJ, Clarkson ABJr, Seed JR, Nathan HC, Amole BO, Hutner SH, Sjoerdsma A (1981) Further studies on difluoromethylornithine in African trypanosomes. Med Biol 59:434-440
21. Metcalf BW, Bey P, Danzin C, Jung MJ, Casara P, Vevert JP (1978) Catalytic irreversible inhibition of mammalian ornithine decarboxylase (E.C.4.1.1.17) by substrate and product analogues. J Am Chem Soc 100:2551-2553
22. Milord F, Pepin J, Loko L, Ethier L, Mpia B (1992) Efficacy and toxicity of eflornithine for treatment of Trypanosoma brucei gambiense sleeping sickness. Lancet 340:652-655
23. Milord F, Loko L, Ethier L, Mpia B, Pepin J (1993) Eflornithine concentrations in serum and cerebrospinal fluid of 63 patients treated for Trypanosoma brucei gambiense sleeping sickness. Trans R Soc Trop Med Hyg 87:473-477
24. Nightingale S (1991) Drug for sleeping sickness approved. JAMA 265:1229
25. Pasic TR, Heisey D, Love RR (1997) Alpha-difluoromethylornithine ototoxicity. Chemoprevention clinical trial results. Arch Otolaryngol Head Neck Surg 123:1281-1286
26. Pegg AE, McCann PP (1982) Polyamine metabolism and function. Am J Physiol 243:C212-221
27. Pegg AE, McGovern KA, Wiest L (1987) Decarboxylation of alpha-difluoromethylornithine by ornithine decarboxylase. Biochem J 241:305-307
28. Pepin J, Ethier L, Kazadi C, Milord F, Ryder R (1992) The impact of human immunodeficiency virus infection on the epidemiology and treatment of Trypanosoma brucei gambiense sleeping sickness in Nioki, Zaire. Am J Trop Med Hyg 47:133-140
29. Pepin J, Khonde N, Maiso F, Doua F, Jaffar S, Ngampo S, Mpia B, Mbulamberi D, Kuzoe F (2000) Short-course eflornithine in Gambian trypanosomiasis: a multicentre randomized controlled trial. Bull World Health Organ 78:1284-1295
30. Van Nieuwenhove S (1992) Advances in sleeping sickness therapy. Ann Soc Belg Med Trop 72:39-51
31. Van Nieuwenhove S, Schechter PJ, Declercq J, Bone G, Burke J, Sjoerdsma A (1985) Treatment of gambiense sleeping sickness in the Sudan with oral DFMO, an inhibitor if ornithine decarboxylase; first field trial. Trans R Soc Trop Med Hyg 79:692-698
32. World Health Organisation (2001) World Health Organization and Aventis announce a major initiative to step up efforts against sleeping sickness. World Health Organisation, Press Release 23